Live news related to ARGENX SE stock (NL0010832176): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on ARGENX SE mainly cover M&A activity, earnings publications et analyst notes. The stock trades at €810,40 on Euronext Paris, up 0,75% at the last update. This page lists the articles published on ARGENX SE stock to track the share price, company announcements and any item likely to influence market perception.
Argenx published its third quarter 2026 financial results on October 22, 2026. Net product sales reached $1,721 million, up 54% year-over-year and 13%…
The Dutch biotechnology company rebounds sharply during the session, after a lackluster low and two days ahead of a quarterly meeting. A price target …
Argenx announced on October 19, 2026, the forthcoming presentation of results from the phase 3 ALKIVIA study in autoimmune myositis, whose primary end…
The decision follows a recommendation from an independent data monitoring committee, which determined following an interim analysis that the study wou…
Argenx obtained, on October 8, 2026, the first clinical readout of FB102 following the acquisition of Forte Biosciences in August 2026, and this Phase…
The immunology group listed on Euronext and Nasdaq announced the presentation of clinical, long-term and real-world data on Vyvgart and candidates fro…
The immunology group listed on Euronext and Nasdaq announced that members of its management team will speak at two financial events organized in the U…
The Dutch immunology group touches a new absolute peak during the session, surpassing the previous record established two days earlier. This spike occ…
The Dutch-based group has finalized the acquisition of the American company at a price of 77 dollars per share. The transaction integrates FB102, an a…
Argenx announced on August 17, 2026 positive primary results for its ALKIVIA phase 3 trial, which evaluated Vyvgart Hytrulo (efgartigimod) in adults w…
